drugset / Trial / NCT03785340

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

NCT03785340

Phase 3 Completed 252 enrolled Ocugen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline (placebo).

Timeline

Start
2018-12-03
Primary completion
2019-02-25
Completion
2019-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.2 % Other

Indications